Education
About Us
Working with TipRanks
Follow Us
Algernon Pharmaceuticals (TSE:AGN)
:AGN
AGN Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.10
Previous CloseN/A
Volume3.18K
Average Volume (3M)13.80K
Market Cap
C$1.86M
Enterprise ValueC$1.19M
Total Cash (Recent Filing)C$210.03K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,499,270
10 Day Avg. Volume14,017
30 Day Avg. Volume13,803
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet materially lowers financial fixed costs and reduces default/interest risk over the coming months. This structural strength preserves optionality for financing or partnerships, extending runway relative to leveraged peers even while the company remains pre-revenue.
Narrowed Losses And Improving Cash BurnMeaningful reduction in operating losses and free cash outflow indicates improved cost discipline or program prioritization. Persisting improvement reduces near-term financing needs, lengthens runway, and increases the probability management can reach value-driving milestones without immediate dilution.
Clinical-stage Pipeline With Legacy Marketed ProductA clinical-stage R&D focus plus an existing marketed product provides dual strategic paths: progress clinical assets toward regulatory/partnership catalysts while monetizing or out-licensing the legacy product. This structural model creates multiple durable value-creation avenues beyond short-term trading.
Bears Say
No Revenue And Negative Gross ProfitZero product or recurring revenue means the business cannot self-fund operations and remains entirely dependent on external capital or licensing events. Persistent negative gross profit signals the company has yet to demonstrate scalable, margin-generating operations.
Persistent Cash Burn & Funding RelianceConsistent negative operating and free cash flow creates an ongoing financing imperative. Over a 2-6 month horizon this increases dilution and execution risk if trial timelines slip or partnerships delay, constraining strategic flexibility until revenue or non-dilutive funding arrives.
Very Small Operational ScaleA single-employee reported headcount signals limited internal capacity to run trials, regulatory work, and commercialization activities. This structural constraint increases dependence on external CROs, partners, or management hires, raising execution risk and potential delays on the critical path.
Algernon Pharmaceuticals News
AGN FAQ
What was Algernon Pharmaceuticals’s price range in the past 12 months?
Algernon Pharmaceuticals lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
What is Algernon Pharmaceuticals’s market cap?
Algernon Pharmaceuticals’s market cap is C$1.86M.
When is Algernon Pharmaceuticals’s upcoming earnings report date?
Algernon Pharmaceuticals’s upcoming earnings report date is May 05, 2026 which is in 71 days.
How were Algernon Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Algernon Pharmaceuticals overvalued?
According to Wall Street analysts Algernon Pharmaceuticals’s price is currently Overvalued.
Does Algernon Pharmaceuticals pay dividends?
Algernon Pharmaceuticals does not currently pay dividends.
What is Algernon Pharmaceuticals’s EPS estimate?
Algernon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Algernon Pharmaceuticals have?
Algernon Pharmaceuticals has 46,499,270 shares outstanding.
What happened to Algernon Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Algernon Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―
Options Prices
Currently, No data available
---